Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks

Sin Gon Kim; Kyoung Jin Kim; Kun Ho Yoon; Sung Wan Chun; Kyong Soo Park; Kyung Mook Choi; Soo Lim; Ji Oh Mok; Hyoung Woo Lee; Ji A. Seo; Bong Soo Cha; Mi Kyung Kim; Ho Sang Shon; Dong Seop Choi; Doo Man Kim

doi:10.1111/dom.14085

Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks

Sin Gon Kim, Kyoung Jin Kim, Kun Ho Yoon, Sung Wan Chun, Kyong Soo Park, Kyung Mook Choi, Soo Lim, Ji Oh Mok, Hyoung Woo Lee, Ji A. Seo, Bong Soo Cha, Mi Kyung Kim, Ho Sang Shon, Dong Seop Choi, Doo Man Kim

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were −0.79% and −0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, −0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (−11.9% vs. −4.8%; P <.0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety.

Original language	English
Pages (from-to)	1869-1873
Number of pages	5
Journal	Diabetes, Obesity and Metabolism
Volume	22
Issue number	10
DOIs	https://doi.org/10.1111/dom.14085
Publication status	Published - 2020 Oct 1
Externally published	Yes

Bibliographical note

Funding Information:
Sin Gon Kim and Kyoung Jin Kim contributed equally to this study as first authors. This study was supported by the Chong Kun Dang Pharmaceutical Corp., Seoul, Republic of Korea. The sponsor participated in the study design, data collection and analysis of the data. The sponsor had no role in the writing of the manuscript or in the decision to submit the manuscript for publication.

Publisher Copyright:
© 2020 John Wiley & Sons Ltd

Keywords

clinical trial
lobeglitazone
randomized trial
thiazolidinediones
type 2 diabetes

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/dom.14085

Cite this

Kim, S. G., Kim, K. J., Yoon, K. H., Chun, S. W., Park, K. S., Choi, K. M., Lim, S., Mok, J. O., Lee, H. W., Seo, J. A., Cha, B. S., Kim, M. K., Shon, H. S., Choi, D. S., & Kim, D. M. (2020). Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks. Diabetes, Obesity and Metabolism, 22(10), 1869-1873. https://doi.org/10.1111/dom.14085

Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks. / Kim, Sin Gon; Kim, Kyoung Jin; Yoon, Kun Ho et al.
In: Diabetes, Obesity and Metabolism, Vol. 22, No. 10, 01.10.2020, p. 1869-1873.

Research output: Contribution to journal › Article › peer-review

Kim, SG, Kim, KJ, Yoon, KH, Chun, SW, Park, KS, Choi, KM, Lim, S, Mok, JO, Lee, HW, Seo, JA, Cha, BS, Kim, MK, Shon, HS, Choi, DS & Kim, DM 2020, 'Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks', Diabetes, Obesity and Metabolism, vol. 22, no. 10, pp. 1869-1873. https://doi.org/10.1111/dom.14085

@article{c4ea6182a3a74a00b6542ef1d220672f,

title = "Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks",

abstract = "We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were −0.79% and −0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, −0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (−11.9% vs. −4.8%; P <.0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety.",

keywords = "clinical trial, lobeglitazone, randomized trial, thiazolidinediones, type 2 diabetes",

author = "Kim, {Sin Gon} and Kim, {Kyoung Jin} and Yoon, {Kun Ho} and Chun, {Sung Wan} and Park, {Kyong Soo} and Choi, {Kyung Mook} and Soo Lim and Mok, {Ji Oh} and Lee, {Hyoung Woo} and Seo, {Ji A.} and Cha, {Bong Soo} and Kim, {Mi Kyung} and Shon, {Ho Sang} and Choi, {Dong Seop} and Kim, {Doo Man}",

note = "Funding Information: Sin Gon Kim and Kyoung Jin Kim contributed equally to this study as first authors. This study was supported by the Chong Kun Dang Pharmaceutical Corp., Seoul, Republic of Korea. The sponsor participated in the study design, data collection and analysis of the data. The sponsor had no role in the writing of the manuscript or in the decision to submit the manuscript for publication. Publisher Copyright: {\textcopyright} 2020 John Wiley & Sons Ltd",

year = "2020",

month = oct,

day = "1",

doi = "10.1111/dom.14085",

language = "English",

volume = "22",

pages = "1869--1873",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "10",

}

TY - JOUR

T1 - Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks

AU - Kim, Sin Gon

AU - Kim, Kyoung Jin

AU - Yoon, Kun Ho

AU - Chun, Sung Wan

AU - Park, Kyong Soo

AU - Choi, Kyung Mook

AU - Lim, Soo

AU - Mok, Ji Oh

AU - Lee, Hyoung Woo

AU - Seo, Ji A.

AU - Cha, Bong Soo

AU - Kim, Mi Kyung

AU - Shon, Ho Sang

AU - Choi, Dong Seop

AU - Kim, Doo Man

N1 - Funding Information: Sin Gon Kim and Kyoung Jin Kim contributed equally to this study as first authors. This study was supported by the Chong Kun Dang Pharmaceutical Corp., Seoul, Republic of Korea. The sponsor participated in the study design, data collection and analysis of the data. The sponsor had no role in the writing of the manuscript or in the decision to submit the manuscript for publication. Publisher Copyright: © 2020 John Wiley & Sons Ltd

PY - 2020/10/1

Y1 - 2020/10/1

N2 - We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were −0.79% and −0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, −0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (−11.9% vs. −4.8%; P <.0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety.

AB - We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were −0.79% and −0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, −0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (−11.9% vs. −4.8%; P <.0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety.

KW - clinical trial

KW - lobeglitazone

KW - randomized trial

KW - thiazolidinediones

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85086589945&partnerID=8YFLogxK

U2 - 10.1111/dom.14085

DO - 10.1111/dom.14085

M3 - Article

C2 - 32406573

AN - SCOPUS:85086589945

SN - 1462-8902

VL - 22

SP - 1869

EP - 1873

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 10

ER -

Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this